

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A medical device for delivering an anti-restenotic composition comprising:

a stent having a generally cylindrical shape comprising an outer surface, an inner surface, a first open end, a second open end and wherein at least one of said inner or said outer surfaces are ~~adapted to deliver an anti-restenotic effective amount of at least one proteasome inhibitor to a tissue within a mammal coated with a polymer comprising an acrylic polymer or copolymer wherein said polymer has bortezomib incorporated therein and said polymer delivers said bortezomib into a tissue of a mammal.~~

Claim 2 (original): The medical device according to claim 1 wherein said stent is mechanically expandable.

Claim 3 (original): The medical device according to claim 1 wherein said stent is self expandable.

Claim 4 (currently amended): The medical device according to claim 1 wherein said ~~at least one proteasome inhibitor bortezomib~~ is present on both said inner surface and said outer surface of said stent.

Claim 5 - claim 10 (canceled):

Claim 11 (currently amended): The medical device according to claim 1 wherein said stent is delivered to said tissue ~~of said anatomical lumen~~ using a balloon catheter.

Claim 12 (original): The medical device according to claim 1 wherein said tissue is a blood vessel lumen.

Claim 13 (canceled):

Claim 14 (currently amended): A vascular stent comprising a polymeric coating containing an anti-restenotic effective amount of ~~a proteasome inhibitor bortezomib wherein said polymer coating comprises an acrylic polymer or copolymer.~~

Claim 15 – claim 16 (canceled):

Claim 17 (currently amended): The vascular stent of ~~claim 1 or~~ claim 14 wherein said ~~proteasome inhibitor bortezomib~~ is in a concentration of between 0.1% to 99% by weight of proteasome inhibitor-to-polymer.

Claim 18 (canceled):

Claim 19 (original): The vascular stent according to claim 14 wherein said stent is delivered to a tissue of a mammal's anatomical lumen using a balloon catheter.

Claim 20 (currently amended): A method for inhibiting restenosis in a mammal comprising the site specific delivery of ~~at least one proteasome inhibitor bortezomib in combination with a polymer comprising an acrylic polymer or copolymer.~~

Claim 21 (currently amended): The method according to claim 20 wherein said ~~proteasome inhibitor bortezomib~~ is delivered to a site at risk for restenosis using a vascular stent.

Claim 22 (currently amended): The method according to claim 20 wherein said ~~proteasome inhibitor bortezomib~~ is delivered to a site at risk for restenosis using an injection catheter.

Claim 23 – claim 24 (canceled):

Claim 25 (currently amended): A method for inhibiting restenosis comprising providing a vascular stent having a coating comprising an anti-restenotic effective amount of bortezomib wherein said coating comprises an acrylic polymer or copolymer.

Claim 26 (new): The medical device of claim 1 wherein said bortezomib is in a concentration of between 0.1% to 99% by weight of bortezomib-to-polymer.

Claim 27 (new): The medical device of claim 1 wherein said medical device delivers an anti-restenotic effective amount of a second proteasome inhibitor.

Claim 28 (new): The vascular stent of claim 14 wherein said vascular stent delivers an anti-restenotic effective amount of a second proteasome inhibitor.